New York State Common Retirement Fund’s Tenaya Therapeutics TNYA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q2
Sell
-7,039
Closed -$4.01K 3339
2025
Q1
$4.01K Hold
7,039
﹤0.01% 3134
2024
Q4
$10.1K Hold
7,039
﹤0.01% 3114
2024
Q3
$13.6K Hold
7,039
﹤0.01% 3080
2024
Q2
$21.8K Buy
7,039
+34
+0.5% +$140 ﹤0.01% 3205
2024
Q1
$36.6K Sell
7,005
-15
-0.2% -$72 ﹤0.01% 3062
2023
Q4
$22.7K Sell
7,020
-109
-2% -$235 ﹤0.01% 3136
2023
Q3
$18.2K Buy
7,129
+155
+2% +$649 ﹤0.01% 3185
2023
Q2
$40.9K Buy
6,974
+73
+1% +$424 ﹤0.01% 3168
2023
Q1
$19.7K Hold
6,901
﹤0.01% 3132
2022
Q4
$13.9K Hold
6,901
﹤0.01% 3201
2022
Q3
$20K Buy
6,901
+47
+0.7% +$219 ﹤0.01% 3221
2022
Q2
$39K Sell
6,854
-15,731
-70% -$127K ﹤0.01% 3235
2022
Q1
$266K Buy
22,585
+10,547
+88% +$128K ﹤0.01% 2698
2021
Q4
$228K Buy
12,038
+9,638
+402% +$210K ﹤0.01% 2824
2021
Q3
$50K Buy
+2,400
New +$51.6K ﹤0.01% 3242

Other funds holding TNYA

New York State Common Retirement Fund's TNYA Position: Q2 2025 in Review

New York State Common Retirement Fund sold out of Tenaya Therapeutics (TNYA) in Q2 2025, closing a stake of 7,039 shares — an estimated $4.01K sold.

New York State Common Retirement Fund first reported a position in TNYA in Q3 2021 and held it in 15 quarters. The position peaked at $266K in Q1 2022. 89 funds tracked by Wall St. Rank hold TNYA as of Q2 2025.

  • New York State Common Retirement Fund reported no remaining Tenaya Therapeutics position as of Q2 2025 after selling out during the quarter.
  • New York State Common Retirement Fund sold 7,039 Tenaya Therapeutics shares in Q2 2025, an estimated $4.01K.
  • New York State Common Retirement Fund first reported a position in Tenaya Therapeutics in Q3 2021 and held it in 15 quarters.
  • New York State Common Retirement Fund's Tenaya Therapeutics position peaked at $266K in Q1 2022.
  • 89 funds tracked by Wall St. Rank held Tenaya Therapeutics as of Q2 2025.

Based on New York State Common Retirement Fund's 13F filing for Q2 2025, filed 13 Aug 2025.